MedPath

Safety and Efficacy of Remimazolam in OPCAB Surgery

Not Applicable
Conditions
Coronary Artery Bypass Surgery
Interventions
Registration Number
NCT05396690
Lead Sponsor
Ajou University School of Medicine
Brief Summary

Remimazolam is a novel short-acting benzodiazepine drug that acts on the benzodiazepine binding site of gamma-aminobutryic acid (GABA) A receptor, is metabolized by esterase, and has a context-sensitive half-time of about 6-7 minutes. Looking at some previous studies using Remimazolam, the safety and efficacy as a general anesthetic have been sufficiently proven.

In particular, compared to intravenous anesthetic agents such as propofol, the action time of anesthetics is relatively longer, but the frequency of hypotension is low. However, most studies have been conducted on patients of American Society Anesthesiologist (ASA) class I-II, and studies on patients with high severity have not yet been sufficiently secured.

Therefore, this study aims to compare the efficacy and safety of Remimazolam as an anesthetic with Sevoflurane in terms of hemodynamics in patients with high severity undergoing OPCAB surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
94
Inclusion Criteria
  • Adult patients 19 years of age or older to receive OPCAB surgery
  • Clinical diagnosis of coronary artery obstructive disease
Exclusion Criteria
  • Ejection fraction < 35% at preoperative ECHO test
  • Mitral regurgitation > grade 2 at preoperative ECHO test
  • Currently using inotropics
  • Currently receiving mechanical support

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
sevoflurane groupSevofluraneAfter injection of 2-5 mg of midazolam and 0.5-1.0 mcg/kg of sufentanil as an induction dose, 1 mg/kg of rocumerone is given intravenously when consciousness is lost, and endotracheal intubation is performed when sufficient muscle relaxation is achieved 2 minutes later. For maintenance of anesthesia, the concentration of sevoflurane and sufentanil effect site concentration is 0.4 to 0.5 to reach the appropriate depth of anesthesia, and the optimal degree of anesthesia is based on maintaining the BIS 35 to 65.
remimazolam groupRemimazolam Injection [Byfavo]In the Remimazolam group as an induction dose 6 mg/kg/h of remimazolam with 0.5-1.0 mcg/kg of sufentanil was injected together. If consciousness was lost, rocumerone 1 mg/kg was given intravenously, and endotracheal intubation was performed when sufficient muscle relaxation was achieved 2 minutes later. Maintenance of anesthesia is achieved by using a programmed infusion pump with remimazolam 1 mg/kg/h (up to 2 mg/kg/h) and sufentanil effect site concentration of 0.4 to 0.5 to reach the appropriate depth of anesthesia. The optimal level of anesthesia is based on maintaining a bispectral index (BIS) of 35-65.
Primary Outcome Measures
NameTimeMethod
cardiac index (T4)5 minutes before operation

The cardiac index (CI) at that time was measured and compared between the two groups.

cardiac index (T5)10 minutes after starting left internal mammary artery dissection

The cardiac index (CI) at that time was measured and compared between the two groups.

cardiac index (T6)10 minutes after starting left anterior descending coronary artery anastomosis

The cardiac index (CI) at that time was measured and compared between the two groups.

cardiac index (T7)10 minutes after starting Y-graft anastomosis of graft vessels

The cardiac index (CI) at that time was measured and compared between the two groups.

Secondary Outcome Measures
NameTimeMethod
NE doseDuring surgery(from induction of anesthesia to end of surgery)

total amount of norepinephrine during OPCAB

Incidence of hypotensionDuring surgery(from induction of anesthesia to end of surgery)

The incidence of hypotension during OPCAB are counted by number which based on the anesthetic record.

Trial Locations

Locations (1)

Ajou University Hospital

🇰🇷

Suwon, Gyeonggido, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath